Last Updated: November 19, 2026

List of Excipients in Branded Drug EPIRUBICIN HYDROCHLORIDE

« Back to Dashboard


Generic Drugs Containing EPIRUBICIN HYDROCHLORIDE

Last updated: September 6, 2026

Epirubicin hydrochloride is a mature anthracycline with limited opportunity for new-molecule exclusivity. The strongest commercial openings are injectable-product improvements: ready-to-use presentations, lower-overfill vials, handling systems for hazardous drugs, differentiated container closures, improved cold-chain robustness, and regional supply of reliable generic products. Excipient innovation is constrained because the product is an intravenous cytotoxic solution with established safety, pH, osmolality, sterility, and stability requirements.

Epirubicin Hydrochloride Excipient Strategy, Patent Position, and Commercial Opportunities

What is the current pharmaceutical formulation of epirubicin hydrochloride?

Epirubicin hydrochloride is an anthracycline topoisomerase II inhibitor used primarily in breast cancer and, in some markets, bladder cancer and other solid tumors. It is administered intravenously and is supplied mainly as a sterile aqueous solution.

Commercial products generally use a simple excipient system:

Formulation element Typical role
Epirubicin hydrochloride Active pharmaceutical ingredient
Water for injection Vehicle
Sodium chloride Tonicity adjustment
Hydrochloric acid or sodium hydroxide pH adjustment
Container closure Sterility, light, and containment protection

U.S. labeling for Ellence identifies epirubicin hydrochloride injection as a sterile solution and lists sodium chloride, hydrochloric acid, and water for injection among the formulation components. The product is supplied in single-dose vials and requires handling as a hazardous drug [1].

The formulation is not excipient-intensive. The principal development challenge is maintaining epirubicin stability while controlling degradation, adsorption, particulate formation, extractables, leachables, and cytotoxic exposure during preparation and administration.

What excipients are most commercially relevant for epirubicin hydrochloride?

The best excipient strategy is conservative. A generic manufacturer should first reproduce the established aqueous composition and then pursue differentiation through presentation, packaging, and in-use performance.

Sodium chloride

Sodium chloride is used to support isotonicity and compatibility with intravenous administration. Its use is commercially attractive because it is familiar to regulators and hospitals, has low cost, and creates limited formulation risk.

The main development issue is concentration control. Excessive ionic strength can affect chemical stability, container interaction, and compatibility with infusion diluents. A manufacturer should avoid adding unnecessary buffers or surfactants unless comparative stability data justify the change.

Hydrochloric acid and pH control

Epirubicin hydrochloride is handled as an acidic solution. Hydrochloric acid can provide pH adjustment without introducing a new pharmacologically active buffer system.

A narrow pH range is preferable. The development program should evaluate:

  • Assay and related substances over shelf life
  • Color changes and precipitation
  • Adsorption to administration sets
  • Stability after dilution in common infusion fluids
  • Compatibility with polyvinyl chloride and non-PVC bags
  • Container closure integrity
  • Stability after exposure to light

The target should be based on the reference product and supported by formal forced-degradation studies rather than selected only for initial assay results.

Buffer systems

Phosphate, citrate, acetate, and other buffers may improve pH control, but they introduce additional regulatory and technical risk. They can change ionic strength, metal-ion interactions, degradation pathways, and compatibility with infusion equipment.

For a conventional generic injection, buffer substitution has limited commercial value unless it provides a demonstrable benefit such as longer in-use stability, improved dilution compatibility, or reduced precipitation risk.

Surfactants and solubilizers

Surfactants are generally unnecessary for a conventional aqueous epirubicin hydrochloride solution. Their use could increase the extractables profile, complicate toxicological assessment, and create new particulate or container-compatibility questions.

They may have a role in liposomal, nanoparticle, or depot research products, but those products would require a substantially different clinical and regulatory development strategy.

What formulation patents protect epirubicin hydrochloride products?

The original composition-of-matter and early product patents for epirubicin hydrochloride are long expired. The commercial product is therefore primarily exposed to generic competition rather than new-molecule patent barriers.

IP category Current commercial relevance
Epirubicin molecule Expired or no longer commercially blocking
Conventional aqueous injection Generally difficult to protect with broad composition claims
Liposomal or nanoparticle delivery Potentially protectable but clinically and regulatorily higher risk
Manufacturing process Potentially protectable if non-obvious and reproducible
Container or administration system Potentially protectable where the system solves a measurable handling problem
Method of use Limited value where treatment methods are established and generic labeling is broad
New combination therapy Potentially protectable, but usually requires clinical evidence

A new patent strategy would need to focus on a specific technical improvement. Examples include a stable low-overfill formulation, a light-protective container system, a closed transfer presentation, a defined dilution-stability profile, or a novel delivery platform.

Broad claims covering “epirubicin hydrochloride in water with sodium chloride” would face substantial novelty and obviousness challenges because the product and its formulation principles are established.

What is the Orange Book status of epirubicin hydrochloride?

The U.S. reference product is Ellence, marketed by Pfizer and approved under NDA 050778. The U.S. product is an injectable formulation of epirubicin hydrochloride [1, 2].

Public FDA Orange Book records should be checked for the current listing status of the reference product, approved abbreviated new drug applications, and any listed patents. The commercial position of epirubicin hydrochloride is generally consistent with a mature generic injectable:

  • No commercially significant active composition-of-matter patent is expected.
  • Conventional generic entry is primarily an ANDA and manufacturing exercise.
  • Any current patent exposure is more likely to involve a product-specific formulation, use, or device claim than the molecule itself.
  • Patent listings, if present, must be evaluated against the exact proposed dosage form and labeling.

Because epirubicin is an old cytotoxic, regulatory exclusivity is not the main barrier. Manufacturing compliance, sterile supply, analytical control, and hazardous-drug handling are more important.

When does epirubicin hydrochloride lose exclusivity?

Epirubicin hydrochloride lost practical exclusivity many years ago. Its primary patents date from the development era of the molecule and are not expected to block current generic development.

Exclusivity type Commercial position
Chemical entity exclusivity Expired
Original product patent protection Expired
New-drug exclusivity Expired
Pediatric exclusivity Not a meaningful commercial barrier
Orphan exclusivity Not generally relevant to the core product
Current generic opportunity Open, subject to regulatory and manufacturing requirements

A company evaluating market entry should focus less on expiry-date modeling and more on whether the target market has an approved reference product, sufficient demand, stable API supply, and an acceptable cytotoxic manufacturing platform.

Which companies are challenging epirubicin hydrochloride exclusivity?

Epirubicin hydrochloride has been subject to generic competition from multiple manufacturers across the United States, Europe, Asia, and emerging markets. The competitive field includes established sterile-injectable companies, hospital-supply manufacturers, and regional oncology-product suppliers.

The major competitive variables are:

  • Approved vial strengths
  • Availability of multiple fill volumes
  • Regional registration status
  • API security
  • Batch-release reliability
  • Pricing and tender access
  • Shortage history
  • Compliance with hazardous-drug manufacturing requirements
  • Ability to supply oncology distributors

The product is not a typical high-growth branded market. Competitive advantage comes from dependable supply and efficient production rather than brand-driven prescribing.

What generic entry risks exist for epirubicin hydrochloride?

Generic entry risk is high because the active ingredient is established, the dosage form is conventional, and the formulation is relatively simple. The principal barriers are operational.

Sterile manufacturing risk

Epirubicin hydrochloride requires aseptic processing or validated terminal sterilization where feasible. The manufacturer must control:

  • Bioburden
  • Endotoxin
  • Particulates
  • Sterility assurance
  • Container closure integrity
  • Cross-contamination with other cytotoxics
  • Personnel and environmental exposure

A dedicated cytotoxic manufacturing area may be required depending on the facility design and local regulation.

Stability risk

Anthracyclines can be sensitive to light, temperature, pH, and dilution conditions. A manufacturer needs stability studies covering:

  • Long-term and accelerated storage
  • Freeze-thaw exposure
  • Shipping excursions
  • Dilution into saline and dextrose solutions
  • In-use storage
  • Infusion-bag compatibility
  • Syringe and administration-set compatibility

A product that matches the reference formulation but has weaker in-use stability may lose hospital tenders even if it meets release specifications.

Supply-chain risk

Epirubicin is a relatively low-volume oncology injectable compared with doxorubicin. Market economics can therefore be affected by small numbers of suppliers, API interruptions, and manufacturing-site failures.

A commercial entrant should secure at least one qualified API source and establish a contingency plan for critical packaging materials. Shortages in mature sterile products can create temporary pricing opportunities, but they can also expose suppliers to regulatory scrutiny and service-level penalties.

What formulation and packaging opportunities exist?

Ready-to-use vials

The most practical opportunity is a ready-to-use solution in common vial sizes. Hospitals value presentations that reduce manipulation and preparation time.

Potential commercial formats include:

  • Small-volume vials for low-dose preparation
  • Larger vials for high-dose regimens
  • Single-dose vials with reduced overfill
  • Color- and light-protective packaging
  • Barcoded unit-dose products

The product must balance fill volume against wastage. Excessive overfill increases cost and can create disposal problems for a high-value cytotoxic drug.

Ready-to-administer infusion bags

A premixed infusion bag could reduce pharmacy compounding, but it creates more complex stability, packaging, and distribution requirements. The bag would need validated shelf life, compatibility with the infusion system, and a practical dose range.

A ready-to-administer product has the greatest potential in hospitals with centralized oncology pharmacies, high epirubicin utilization, or limited compounding capacity.

Closed-system transfer compatibility

A vial and closure designed for use with closed-system transfer devices could provide a commercial advantage. The value is operational rather than pharmacological. Product development should evaluate stopper puncture performance, coring, pressure behavior, extractables, and compatibility with commonly used transfer devices.

A proprietary closure or adapter may support device-related patent claims, but the clinical and purchasing benefit must be clear enough to justify a higher price.

Light-protective containers

A light-protective vial, secondary carton, or overwrap can reduce handling risk and support product stability. Packaging claims are most defensible when linked to measured protection against degradation under defined exposure conditions.

Lyophilized formulations

A lyophilized epirubicin hydrochloride product could improve some aspects of shipping or long-term stability, but it would require reconstitution before use. The format may add preparation steps and increase medication-error risk.

Lyophilization is therefore more attractive where liquid stability, regional distribution, or temperature excursions are substantial problems. It is less attractive where hospitals already prefer ready-to-use liquid products.

How strong is the epirubicin hydrochloride patent estate?

The patent estate is weak for the conventional product and potentially moderate for narrowly defined delivery or manufacturing improvements.

Patent strategy Likely strength
Basic aqueous epirubicin solution Low
Specific concentration and pH range Low to moderate, depending on prior art and unexpected results
Liposomal formulation Moderate to high if supported by clinical data
Nanoparticle delivery Moderate, but development risk is high
Closed-system container Moderate if technically specific
Manufacturing impurity-control process Moderate if it produces a measurable quality advantage
New combination or dosing regimen Moderate, subject to obviousness and clinical support

Patent value should be assessed claim by claim. A narrow process patent may protect a manufacturing route but have little value if competitors can use an alternative process. A container patent may have commercial value only if hospitals standardize on the protected system.

What licensing deals and partnership opportunities exist?

Large upfront licensing deals are unlikely for the conventional epirubicin injection because the molecule is generic and the market is mature. More realistic transactions include:

  • Regional distribution agreements
  • Contract manufacturing arrangements
  • API supply agreements
  • Co-development of premixed oncology products
  • Licensing of closed-system transfer technology
  • Hospital-tender partnerships
  • Acquisition of approved injectable registrations

The most valuable asset may be a compliant sterile manufacturing site with existing oncology-product approvals. A buyer or licensee can reduce development time by using an established quality system, validated facilities, and existing regulatory relationships.

What is the biosimilar risk for epirubicin hydrochloride?

Biosimilar risk is not relevant. Epirubicin hydrochloride is a small-molecule chemical drug, not a biologic. Competitive entry occurs through generic-drug pathways such as an ANDA in the United States or equivalent national and regional procedures elsewhere.

This distinction matters commercially. A competitor does not need to establish biosimilarity, immunogenicity, or a biologics manufacturing platform. The principal requirements are pharmaceutical equivalence, bioequivalence where applicable, quality, sterility, labeling, and manufacturing compliance [2, 3].

How does epirubicin compare with doxorubicin commercially?

Epirubicin competes most directly with doxorubicin in anthracycline oncology, but the products are not interchangeable solely because they belong to the same class.

Attribute Epirubicin hydrochloride Doxorubicin hydrochloride
Drug class Anthracycline Anthracycline
Main commercial form Sterile injection Sterile injection, including conventional and liposomal products
Generic maturity High High
Formulation complexity Low for conventional injection Low for conventional injection; higher for liposomal products
Key differentiation Regimen selection, supply, packaging Broad product range and liposomal delivery
Patent opportunity Formulation, packaging, manufacturing Greater opportunity in liposomal and delivery systems
Main commercial risk Price competition and supply reliability Competition across conventional and specialty formulations

Doxorubicin has a broader commercial ecosystem, including liposomal products such as Doxil. Epirubicin has fewer high-value differentiated formulations, which limits premium-pricing opportunities but simplifies development of conventional generic presentations.

What is the likely commercial opportunity?

The best opportunity is a regulated, reliable, low-waste injectable product supported by differentiated logistics.

A practical product strategy would prioritize:

  1. A conventional aqueous solution matching the reference composition.
  2. Multiple vial sizes with controlled overfill.
  3. Light-protective packaging.
  4. Demonstrated dilution and in-use stability.
  5. Compatibility with hazardous-drug transfer systems.
  6. Regional registrations in markets with oncology-tender demand.
  7. Dual API sourcing and validated supply continuity.
  8. Optional premixed bags for high-volume hospital customers.

Premium pricing is unlikely for a standard vial. Margin improvement is more likely through lower manufacturing cost, reduced pharmacy waste, improved fill-finish efficiency, reliable supply, and institutional contracts.

Key Takeaways

  • Epirubicin hydrochloride is a mature generic anthracycline with no meaningful new-molecule exclusivity remaining.
  • The conventional formulation is a simple sterile aqueous solution using water for injection, sodium chloride, and pH adjustment.
  • Excipient changes should be limited because unnecessary buffers and surfactants add regulatory and compatibility risk.
  • The strongest commercial opportunities are ready-to-use vials, premixed bags, low-overfill presentations, light protection, and closed-system transfer compatibility.
  • The patent estate is weak for the basic injection but may support narrow claims covering delivery systems, packaging, or manufacturing controls.
  • Biosimilar competition does not apply; generic competition does.
  • The main barriers are sterile cytotoxic manufacturing, stability, supply continuity, regulatory approvals, and hospital-tender economics.
  • Doxorubicin has a broader differentiated-product landscape, especially through liposomal delivery, while epirubicin is more dependent on reliable conventional injection supply.

FAQs

Is epirubicin hydrochloride compatible with normal saline?

Commercial products are commonly diluted in compatible intravenous solutions such as sodium chloride injection, subject to the approved product labeling and validated in-use stability data. Compatibility should be established for the specific concentration, container, administration set, and storage period.

Can epirubicin hydrochloride be formulated without sodium chloride?

A sodium-chloride-free formulation may be technically possible, but it would require control of tonicity, pH, stability, and intravenous tolerability. Removing sodium chloride does not create a commercial advantage unless it solves a defined compatibility or clinical-use problem.

Is a liposomal epirubicin product commercially attractive?

It could be differentiated, but the opportunity would require new pharmacokinetic, safety, efficacy, manufacturing, and regulatory work. Liposomal delivery offers more patent potential than a conventional injection but carries substantially higher development cost and clinical risk.

What packaging is best for epirubicin hydrochloride?

A single-dose, light-protective vial with a validated elastomeric closure is the lowest-risk commercial format. A proprietary closure or transfer-compatible package may support differentiation if it reduces exposure, waste, or preparation time.

Does epirubicin hydrochloride require a dedicated manufacturing facility?

Not necessarily a facility dedicated only to epirubicin, but the site must have validated controls for cytotoxic products, including segregation or campaign controls, cleaning validation, personnel protection, environmental controls, and cross-contamination prevention.

References

  1. Pfizer Inc. (2023). Ellence (epirubicin hydrochloride injection) prescribing information. U.S. Food and Drug Administration.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

  3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA, Center for Drug Evaluation and Research.

  4. European Medicines Agency. (2024). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. EMA.

  5. U.S. Pharmacopeia. (2024). General chapter <800>: Hazardous drugs: Handling in healthcare settings. United States Pharmacopeial Convention.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.